Sitaxentan
As of the edition of 20 October 2026, Sitaxentan is a small molecule: withdrawn from the market in 2011; acts on EDNRA and EDNRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2011
- Kind
- Small molecule
- Withdrawn from market
- 6 January 2011 (worldwide)
- Registered trials
- 20, 11 stopped early
- Disease areas
- Lungs and airways; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 2 |
| Phase 1 | 5 | 2 | 0 | 3 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 8 | 1 | 0 | 6 |
| All trials | 20 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2003 to now |